ABSTRACT:
Primrose Bio’s Pfenex Expression Technology® (Pfenex) platform has established itself as a robust, scalable solution for recombinant protein production, as evidenced by its role in six commercially approved products. Integrating sophisticated high-throughput screening, comprehensive analytics, and optimized upstream and downstream processes, the Pfenex platform delivers high-titer protein production strains in a mere 10 days through our innovative Pfast™ Feasibility workflows. Pfenex has the ability to perform culture-to-protein enrichment at 96-well scale, transforming it into a powerful tool for evaluating molecular variants with genuine high-throughput capabilities. To illustrate recent breakthroughs in Pfenex’s high-throughput purification capabilities, we present a use case for screening RNA polymerase variants. Utilizing Cytiva’s™ Protein Select™ technology, we demonstrated successful purification of untagged, active enzyme variants of up to 80ug from individual wells in a 96-well format. The high-titer strains developed through Pfenex workflows have exceptional compatibility with Protein Select.